现在的位置: 首页时讯速递, 进展交流>正文
[JAMA Intern Med发表论文]:奥司他韦预防门诊患者因流感住院
2024年02月11日 时讯速递, 进展交流 [JAMA Intern Med发表论文]:奥司他韦预防门诊患者因流感住院已关闭评论

Original Investigation 

June 12, 2023

Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis

Ryan Hanula, Émilie Bortolussi-Courval, Arielle Mendel, et al

JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699

Key Points

Question  Is the administration of oseltamivir to adult and adolescent outpatients with confirmed influenza associated with a reduced risk of first hospitalization?

Findings  In this systematic review and meta-analysis of 15 randomized clinical trials including 6166 patients, oseltamivir was not associated with reduced risk of first hospitalization compared with placebo or standard of care. Results were similar in a subgroup of patients considered at high risk of hospitalization; however, the CIs were wide.

Meaning  An adequately powered trial in a suitably high-risk population is needed to determine who might benefit from early treatment with oseltamivir to prevent hospitalization.

Abstract

Importance  Despite widespread use, summary evidence from prior meta-analyses has contradictory conclusions regarding whether oseltamivir decreases the risk of hospitalization when given to outpatients. Several large investigator-initiated randomized clinical trials have not yet been meta-analyzed.

Objective  To assess the efficacy and safety of oseltamivir in preventing hospitalization among influenza-infected adult and adolescent outpatients.

Data Sources  PubMed, Ovid MEDLINE, Embase, Europe PubMed Central, Web of Science, Cochrane Central, ClinicalTrials.gov, and WHO International Clinical Trials Registry were searched from inception to January 4, 2022.

Study Selection  Included studies were randomized clinical trials comparing oseltamivir vs placebo or nonactive controls in outpatients with confirmed influenza infection.

Data Extraction and Synthesis  In this systematic review and meta-analysis, Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed. Two independent reviewers (R.H. and É.B.C.) extracted data and assessed risk of bias using the Cochrane Risk of Bias Tool 2.0. Each effect size was pooled using a restricted maximum likelihood random effects model. The quality of evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework.

Main Outcomes and Measures  Hospitalization was pooled as risk ratio (RR) and risk difference (RD) estimates with 95% CIs.

Results  Of 2352 studies identified, 15 were included. The intention-to-treat infected (ITTi) population was comprised of 6166 individuals with 54.7% prescribed oseltamivir. Across study populations, 53.9% (5610 of 10 471) were female and the mean age was 45.3 (14.5) years. Overall, oseltamivir was not associated with reduced risk of hospitalization within the ITTi population (RR, 0.79; 95% CI, 0.48 to 1.29; RD, −0.17%; 95% CI, −0.23% to 0.48%). Oseltamivir was also not associated with reduced hospitalization in older populations (mean age ≥65 years: RR, 1.01; 95% CI, 0.21 to 4.90) or in patients considered at greater risk of hospitalization (RR, 0.65; 0.33 to 1.28). Within the safety population, oseltamivir was associated with increased nausea (RR, 1.43; 95% CI, 1.13 to 1.82) and vomiting (RR, 1.83; 95% CI, 1.28 to 2.63) but not serious adverse events (RR, 0.71; 95% CI, 0.46 to1.08).

Conclusions and Relevance  In this systematic review and meta-analysis among influenza-infected outpatients, oseltamivir was not associated with a reduced risk of hospitalization but was associated with increased gastrointestinal adverse events. To justify continued use for this purpose, an adequately powered trial in a suitably high-risk population is justified.

抱歉!评论已关闭.

×
腾讯微博